Making Expedited Regulatory Pathways Work for Global Drug Development Programs

Article from December 2021 edition of Applied Clinical Trials. Parexel regulatory experts offer top tips for working with regulators on a global scale.

Download PDF

Biotech Resources

Making Expedited Regulatory Pathways Work for Global Drug Development Programs

Five strategies for meeting the requirements of Project Optimus and improving the chances of approval

EU Orphan Drug Designation – overcoming regulatory challenges

How to better prepare patients for a cell or gene therapy trial

How biotechs can strengthen their value story with advanced analytics

Want to run a patient-centric rare disease trial? Be site-centric

New endpoints for early-stage cancer are gaining regulatory traction

Five lessons for building an external control arm that regulators can use

How emerging biotechs can enter the Chinese market and prosper

Decentralized trial tools and technologies are here to stay: A regulatory perspective

Maximize the efficiency of regulatory operations with five key competencies

Lessons from China and the United States on the use of RWE in regulatory submissions

Can Synthetic / External Control Arms meet regulatory and HTA requirements?

4 insights on decentralized trials for biotechs _ BioPharma Dive.PXRL

Multi-stakeholder strategies for external control arms

How a joined-up development strategy pays off for early-stage biotechs

Navigating COVID-19 to Support Next-Gen Patient-Focused Treatments

How to accelerate oncology clinical trials through site relationships and patient insights

Decentralized clinical trials - A more patient-centric approach

Four Keys to a Smoother Clinical Development Journey

Entering a new age of evidence generation: synthetic control models